Exelixis reports Phase III trial results of prostate cancer drug cabozantinib

September 2, 2014 3:23 PM

3 0

US-based biopharmaceutical firm Exelixis has released top-line results from the final analysis of the Phase III COMET-1 trial of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC).

The COMET-1 trial evaluated cabozantinib in mCRPC patients whose disease progressed after treatment with docetaxel as well as abiraterone and/or enzalutamide.

Also read: Deutsche Bank Gets a Much-Needed Boost Working for Big Tobacco

Read more

To category page